# Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

> **NCT01323062** · PHASE1 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Bavituximab

## Key facts

- **NCT ID:** NCT01323062
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-05-14
- **Final completion:** 2018-10-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323062, "Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01323062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*